Back to News
Oct 31, 2025 12:00 PM

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.

Sales increased 9.1% on a reported basis or 8.4% on an operational basis. The company reported adjusted earnings of $1.86 per share, down 38%, beating the consensus of $1.79.

Dividend: AbbVie increased its quarterly dividend from $1.64 per share to $1.73.

“AbbVie continues to deliver outstanding results, with significant momentum across key areas of our portfolio. We are also making great progress advancing our pipeline and investing in innovation to support AbbVie’s long-term growth,” said Robert Michael, chairman and CEO, AbbVie. “Based upon the strength of our business and its promising outlook, we are once again raising our quarterly cash dividend.”

Also Read: AbbVie’s Botox Shows Improvement In Movement Disorder Study

Global net revenues from the ...